Second Quarter 2026 Results / Half-Year Financial Report
Bayer Q2 2026 Media Update
Bayer operationally on track, decisive progress on strategic priorities
- Group sales increase 2.2 percent (Fx & portfolio adj.) to 10.872 billion euros
- EBITDA before special items rises 1.9 percent to 2.144 billion euros
- EBITDA before special items rises 1.9 percent to 2.144 billion euros
- Pharmaceuticals sales at prior-year level, earnings down
- Consumer Health registers slightly higher sales and lower earnings
- Core earnings per share at 0.95 euros, 16.7 percent below prior year
- Net income improves to 219 million euros
- Free cash flow declines to minus 371 million euros, partly due to settlement payments
- Net financial debt at 33.647 billion euros
- Currency-adjusted Group outlook confirmed, with net financial debt to be lower than originally projected
- Company focused on advancing its strategic priorities
Strategy and Financial Update
Bayer CEO Bill Anderson shares an overview of where Bayer stands at the half-year mark – in 90 seconds.
Media Update Recording
Speaker
CFO of Bayer AG | CEO of Bayer AG |